Seeking Alpha

Zoetis (ZTS)

  • Fri, Jun. 26, 11:04 AM
    • So much for yesterday's up move. Zoetis (ZTS -9.8%) does a quick round trip on 3x higher volume after CNBC's David Faber reported that Valeant Pharmaceuticals (VRX -1.7%) is unlikely to pursue a merger. Apparently, it reached out to Zoetis as a courtesy to significant shareholder Bill Ackman.
    | Fri, Jun. 26, 11:04 AM | 18 Comments
  • Thu, Jun. 25, 4:07 PM
    • Zoetis (NYSE:ZTS) spurted upward near the close to finish the day up 12%. Market chatter says Valeant Pharmaceuticals (NYSE:VRX) has made a bid for the animal health firm. Trading in ZTS is currently halted.
    • Update: ZTS trading resumed.
    | Thu, Jun. 25, 4:07 PM | 8 Comments
  • Fri, May 29, 12:19 PM
    • Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) current #5 rank in the global animal health market could change once it divests its low margin plastics business either via an IPO or direct sale, possibly to a private equity firm. Analysts believe the unit could fetch as much as 11B euros ($12.1B).
    • CEO Marijn Dekkers says animal health is a "very attractive business for us. We've always looked with interest in it. It hasn't happened with us yet."
    • The top acquisition target would be Zoetis (ZTS +0.8%) which generated $4.8B in sales in 2014. Bayer will probably have competition, though. Valeant Pharmaceuticals (VRX -1.7%) and Merck (MRK +0.2%) have been mentioned as likely suitors.
    | Fri, May 29, 12:19 PM | 6 Comments
  • Tue, Feb. 10, 4:41 PM
    • Zoetis (NYSE:ZTS) finalizes its purchase of Abbott's animal health assets for $255M. The integration of the business into its operations is expected to impact this year's performance as follows:
    • Additional revenue: ~$75M; a negative impact on reported EPS of ($0.03); a positive impact of $0.01 on non-GAAP EPS.
    • Previously: Zoetis buys Abbott's animal health business (Nov. 17, 2014)
    | Tue, Feb. 10, 4:41 PM | Comment!
  • Nov. 17, 2014, 9:16 AM
    • Zoetis (NYSE:ZTS) acquires Abbott (NYSE:ABT) division Abbott Animal Health, a companion animal health business focused on the veterinary surgical suite, for $255M.
    • The transaction should close in Q1 2015.
    | Nov. 17, 2014, 9:16 AM | Comment!
  • Nov. 11, 2014, 4:16 PM
    • The presence of Pershing Square's Bill Ackman on the list of major investors in Zoetis (NYSE:ZTS) sends a clear signal that it may be an acquisition target by none other than Valeant Pharmaceuticals (NYSE:VRX). A deal is not out of the question in light of its diminishing prospects of acquiring Allergan (NYSE:AGN) since Actavis (NYSE:ACT) joined the mix.
    • In after hours trading, VRX is up a fraction and ZTS is unchanged, both on higher-than-normal volume.
    • Previously: Zoetis jumps 6% on report of Ackman stake
    | Nov. 11, 2014, 4:16 PM | 1 Comment
  • Nov. 11, 2014, 3:48 PM
    • Bill Ackman's Pershing Square has taken a ~$2B stake in Zoetis (NYSE:ZTS), and may push for a sale to a large drug maker like Valeant Pharmaceuticals (NYSE:VRX), sources tell Dow Jones.
    • The stake would amount to ~10% of Zoetis, and includes an investment by fellow hedge fund Sachem Head Capital Management.
    • ZTS recently +7.2%.
    • Related: Zoetis CEO Juan Alaix on Q3 2014 Results
    | Nov. 11, 2014, 3:48 PM | 2 Comments
ZTS vs. ETF Alternatives
Company Description
Zoetis Inc discovers, develops, manufactures & commercializes animal health medicines & vaccines for livestock & companion animals. Its products include anti-infectives, vaccines, parasiticides, medicated feed additives & other pharmaceutical products.